Haldane A, Finlay G J, Gavin J B, Baguley B C
Cancer Research Laboratory, University of Auckland School of Medicine, New Zealand.
Cancer Chemother Pharmacol. 1992;29(6):475-9. doi: 10.1007/BF00684851.
The cytotoxicity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC 601,316), a new experimental DNA-intercalating antitumor drug, against a cultured Lewis lung adenocarcinoma cell line was compared with that of the DNA-intercalating antitumor drug amsacrine. In contrast to amsacrine, AC demonstrated self-inhibition of cytotoxicity following short (3-9 h) incubation periods and exponential killing (with a shoulder) after long (24-72 h) periods of incubation. The difference between these drugs was best demonstrated using a constant concentration x time (C x T) exposure (AC, 12 mumol h l-1; amsacrine, 3 mumol h l-1). In contrast to amsacrine, AC was minimally effective over exposure periods of less than or equal to 1 h and maximally effective over intermediate periods (4-6 h). The results suggest the possibility of designing AC administration protocols that maximise the drug's cytotoxicity towards solid tumors, which, because of diffusion barriers, are subjected to longer drug exposures than are well-vascularised tumours.
将新型实验性DNA嵌入抗肿瘤药物N-[2-(二甲氨基)乙基]吖啶-4-羧酰胺(AC;NSC 601,316)对培养的Lewis肺癌细胞系的细胞毒性与DNA嵌入抗肿瘤药物安吖啶进行了比较。与安吖啶不同,AC在短时间(3 - 9小时)孵育后表现出细胞毒性的自我抑制,而在长时间(24 - 72小时)孵育后表现出指数性杀伤(伴有一个平台期)。使用恒定浓度×时间(C×T)暴露(AC,12 μmol·h·l-1;安吖啶,3 μmol·h·l-1)能最好地体现这两种药物之间的差异。与安吖啶不同,AC在暴露时间小于或等于1小时时效果最小,而在中间时间段(4 - 6小时)效果最大。结果表明,有可能设计出AC给药方案,使该药物对实体瘤的细胞毒性最大化,由于扩散障碍,实体瘤比血管丰富的肿瘤受到更长时间的药物暴露。